EndoPredict is a 2nd generation breast cancer recurrence test that combines the prognostic power of a 12-Gene Molecular Score with tumor size and lymph node status. EndoPredict provides a comprehensive assessment of the 10-year risk of distant recurrence for women with ER+, HER2- early-stage breast cancer when treated with 5-years of endocrine therapy.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence, particularly in oncology.
Website : www.endopredict.fr
Contact : firstname.lastname@example.org
Address : 13, rue Camille Desmoulins – 92441 Issy-les-Moulineaux – France